Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 10
2008 7
2009 2
2010 7
2011 5
2012 10
2013 10
2014 8
2015 4
2016 5
2017 6
2018 5
2019 4
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

78 results
Results by year
Filters applied: . Clear all
Page 1
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Locatelli F, et al. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1701-1710. doi: 10.2215/CJN.01380219. Epub 2019 Aug 16. Clin J Am Soc Nephrol. 2019. PMID: 31420350 Free PMC article. Clinical Trial.
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta with those of the shorter-acting agents epoetin alfa/beta and darbepoetin alfa in patients with anemia of …
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoe
Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.
Curran MP, McCormack PL. Curran MP, et al. Drugs. 2008;68(8):1139-56. doi: 10.2165/00003495-200868080-00009. Drugs. 2008. PMID: 18484803 Review.
Methoxy polyethylene glycol-epoetin beta (Mircera) is a continuous erythropoietin receptor activator, with a long half-life (approximately 130 hours). ...Methoxy polyethylene glycol-epoetin
Methoxy polyethylene glycol-epoetin beta (Mircera) is a continuous erythropoietin recept
Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.
Schmid H. Schmid H. Expert Rev Hematol. 2016 Jan;9(1):5-20. doi: 10.1586/17474086.2016.1112734. Epub 2015 Nov 17. Expert Rev Hematol. 2016. PMID: 26573694 Review.
Since more than two decades erythropoiesis-stimulating agents are the main pillar for treatment of anemia associated with chronic kidney disease. Methoxy polyethylene glycol-epoetin beta (MPG-EPO), also called continuous erythropoietin
Since more than two decades erythropoiesis-stimulating agents are the main pillar for treatment of anemia associated with chronic kidney dis …
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Palmer SC, et al. Cochrane Database Syst Rev. 2014 Dec 8;2014(12):CD010590. doi: 10.1002/14651858.CD010590.pub2. Cochrane Database Syst Rev. 2014. PMID: 25486075 Free PMC article. Review.
SELECTION CRITERIA: Randomised controlled trials (RCTs) that included a comparison of an ESA (epoetin alfa, epoetin beta, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta, or biosimilar ESA) with another ESA, place …
SELECTION CRITERIA: Randomised controlled trials (RCTs) that included a comparison of an ESA (epoetin alfa, epoetin beta
Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease.
Ohashi N, Sakao Y, Yasuda H, Kato A, Fujigaki Y. Ohashi N, et al. Int J Nephrol Renovasc Dis. 2012;5:53-60. doi: 10.2147/IJNRD.S23447. Epub 2012 Mar 30. Int J Nephrol Renovasc Dis. 2012. PMID: 22536082 Free PMC article.
Methoxy polyethylene glycol-epoetin beta (MPG-EPO) is the only ESA that is generated by chemical modification of glycosylated erythropoietin through the integration of one specific, long, linear chain of polyethylene glycol.
Methoxy polyethylene glycol-epoetin beta (MPG-EPO) is the only ESA that is generated by chemical modifica
Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
Alsalimy N, Awaisu A. Alsalimy N, et al. Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Epub 2014 Oct 7. Int J Clin Pharm. 2014. PMID: 25288147 Review.
Different reviews have focused on evaluating the safety and efficacy of methoxy polyethylene glycol-epoetin beta (MPG-EPO), a continuous erythropoietin receptor activator, in CKD patients regardless of dialysis depend …
Different reviews have focused on evaluating the safety and efficacy of methoxy polyethylene glycol-epoetin b
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Saglimbene VM, et al. Cochrane Database Syst Rev. 2017 Aug 7;8(8):CD009904. doi: 10.1002/14651858.CD009904.pub2. Cochrane Database Syst Rev. 2017. PMID: 28782299 Free PMC article. Review.
BACKGROUND: Continuous erythropoiesis receptor activator (CERA) is a newer, longer acting ESA which might be preferred to other ESAs (epoetin or darbepoetin) based on its lower frequency of administration. ...One study compared CERA with placebo, nine …
BACKGROUND: Continuous erythropoiesis receptor activator (CERA) is a newer, longer acting ESA which might be preferred …
[Switch of methoxy-polyethylene-glycol-epoetin beta to darbepoetin alfa in 263 dialysis patients].
Rieger J, Krummel T, Petitjean P, Chantrel F, Dimitrov Y. Rieger J, et al. Ann Pharm Fr. 2016 Jan;74(1):45-8. doi: 10.1016/j.pharma.2015.06.005. Epub 2015 Jul 17. Ann Pharm Fr. 2016. PMID: 26194063 French.
In early 2012, due to national supply disruption, the methoxy-polyethylene glycol-epoetin beta (CERA) was no longer available and has been replaced by darbepoetin alfa (DA) in all dialysis patients. ...
In early 2012, due to national supply disruption, the methoxy-polyethylene glycol-epoetin beta (CERA) was …
Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).
Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D; MAXIMA study investigators. Levin NW, et al. Lancet. 2007 Oct 20;370(9596):1415-21. doi: 10.1016/S0140-6736(07)61599-2. Lancet. 2007. PMID: 17950856 Clinical Trial.
We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemoglobin control in haemodialysis patients. .. …
We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at …
78 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page